Pneumococcal Vaccination in Korean Adults: 2025 Recommendations by the Korean Society of Infectious Diseases
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The 20-valent pneumococcal conjugate vaccine (PCV20) was approved by the Korean Ministry of Food and Drug Safety in October 2024. Despite the ongoing national immunization programs that include pneumococcal conjugate vaccines for children and 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults, the burden of invasive pneumococcal disease and pneumococcal community-acquired pneumonia remains high among the elderly and high-risk adults. Serotypes 3 and 19A, both included in 13-valent pneumococcal conjugate vaccine (PCV13), continue to be the most prevalent serotypes, and infections caused by non-PCV13 serotypes have increased. Given the need to broaden serotype coverage and simplify vaccination strategies, the Korean Society of Infectious Diseases recommends either a single dose of PCV20 or sequential vaccination with 15-valent pneumococcal conjugate vaccine followed by PPSV23 for adults aged 65 years and older, and for high-risk adults aged 19–64 years. These recommendations are based on immunogenicity, safety, and cost-effectiveness data from recent clinical trials. Vaccine selection, dosing intervals, and schedules should be determined according to individual underlying medical conditions and previous vaccination history to optimize protection against pneumococcal disease in the adult population.
Abstract
The 20-valent pneumococcal conjugate vaccine (PCV20) was approved by the Korean Ministry of Food and Drug Safety in October 2024. Despite the ongoing national immunization programs that include pneumococcal conjugate vaccines for children and 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults, the burden of invasive pneumococcal disease and pneumococcal community-acquired pneumonia remains high among the elderly and high-risk adults. Serotypes 3 and 19A, both included in 13-valent pneumococcal conjugate vaccine (PCV13), continue to be the most prevalent serotypes, and infections caused by non-PCV13 serotypes have increased. Given the need to broaden serotype coverage and simplify vaccination strategies, the Korean Society of Infectious Diseases recommends either a single dose of PCV20 or sequential vaccination with 15-valent pneumococcal conjugate vaccine followed by PPSV23 for adults aged 65 years and older, and for high-risk adults aged 19–64 years. These recommendations are based on immunogenicity, safety, and cost-effectiveness data from recent clinical trials. Vaccine selection, dosing intervals, and schedules should be determined according to individual underlying medical conditions and previous vaccination history to optimize protection against pneumococcal disease in the adult population.